National Bank of Canada
RNAM

National Bank of Canada’s Avidity Biosciences RNAM Stock Holding History

National Bank of Canada’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-581
Closed -$26.7K – 3167
2024
Q3 		$26.7K Buy
+581
New +$25.2K ﹤0.01% 1870
2024
Q1 		– Sell
-1,500
Closed -$13.7K – 2891
2023
Q4 		$13.7K Buy
+1,500
New +$10K ﹤0.01% 2098

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

National Bank of Canada's RNAM Position: Q4 2024 in Review

National Bank of Canada sold out of Avidity Biosciences (RNAM) in Q4 2024, closing a stake of 581 shares — an estimated $26.7K sold.

National Bank of Canada first reported a position in RNAM in Q4 2023 and held it in 2 quarters. The position peaked at $26.7K in Q3 2024. 236 funds tracked by Wall St. Rank hold RNAM as of Q4 2024.

  • National Bank of Canada reported no remaining Avidity Biosciences position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 581 Avidity Biosciences shares in Q4 2024, an estimated $26.7K.
  • National Bank of Canada first reported a position in Avidity Biosciences in Q4 2023 and held it in 2 quarters.
  • National Bank of Canada's Avidity Biosciences position peaked at $26.7K in Q3 2024.
  • 236 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.